Page 6 - Junshi Bioscience News Today

Toripalimab in combination with chemotherapy was associated with significant improvements in PFS and OS compared with chemotherapy alone in patients with advanced NSCLC without EGFR/ALK mutations, regardless

Investegate announcements from Junshi Biosciences, Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Non-squamous Non-Small Cell Lung Cancer

--6th approved indication of toripalimab in China, bringing more treatment options to patients with advanced NSCLCSHANGHAI, China, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd

-- Clinical trials of core drug candidates are progressing steadily with the debut of the company's FIH asset -- Toripalimab's sales performance is consistently improving; the US BLA is under review SHANGHAI

-- the 7th innovative drug in Junshi Biosciences' pipeline to get IND approval from the US FDASHANGHAI, China, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences"

Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor)

-- Additional indications: treatment for Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis and pediatric...

-- Additional indications: treatment for Crohn's disease, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis and pediatric Crohn's disease SHANGHAI, China, Aug. 17, 2022

Ascletis Pharma (ASCLF) is ready to put its new Covid drug into clinical trials, but the firm is lagging in the race to bring similar medicines to market. Read more.

--Favorable preliminary safety and efficacy data for anti-BTLA monoclonal antibody, icatolimab, for the treatment of lymphoma and solid tumors ...